STOCK TITAN
  1. Home
  2. Sec-filings
  3. PLSE
  4. [Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity

Pulse Biosciences (PLSE) COO buys stock in two August trades

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

PULSE BIOSCIENCES, INC. (PLSE) reported that Chief Operating Officer Liane Rae Teplitsky purchased common stock in two open-market transactions. On August 26, 2026 she bought 1,036 shares at $48.235 per share, and on August 28, 2026 she bought 1,034 shares at $48.35 per share, during an open trading window under the company’s Insider Trading Policy. Fractional-share amounts were rounded down, and same-price trades on each day were aggregated into single reported lines.

Positive

  • None.

Negative

  • None.
Insider Teplitsky Liane Rae
Role Chief Operating Officer
Bought 2,070 shs ($100K)
Type Security Shares Price Value
Purchase Common Stock F1, F2, F3 1,034 $48.35 $50K
Purchase Common Stock F1, F2, F3 1,036 $48.235 $50K
Holdings After Transaction: Common Stock — 2,070 shares (Direct)
Footnotes (3)
  1. F1. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.
  2. F2. The purchase of fractional shares has been rounded down to the nearest whole number.
  3. F3. Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price.
Shares purchased (Aug 26, 2026) 1,036 shares of Common Stock Open-market purchase by COO at $48.235 per share
Purchase price (Aug 26, 2026) $48.235 per share Price for 1,036-share open-market purchase by COO
Shares purchased (Aug 28, 2026) 1,034 shares of Common Stock Open-market purchase by COO at $48.35 per share
Purchase price (Aug 28, 2026) $48.35 per share Price for 1,034-share open-market purchase by COO
Total shares purchased 2,070 shares of Common Stock Sum of both reported open-market purchases by COO
open trading window regulatory
"The shares were purchased during an open trading window under the Company's Insider Trading Policy"
A designated period when company executives, directors and certain employees are permitted to buy or sell their employer’s stock under the company’s trading policy because material information has been disclosed. Think of it like scheduled store hours after a big delivery: it reduces the risk of trading on secret information, and investors watch insider activity during these windows as a signal of how those closest to the business view its prospects.
Insider Trading Policy regulatory
"during an open trading window under the Company's Insider Trading Policy"
A written set of rules that tells employees, executives and board members what information they may not use to buy or sell a company's stock and when trading is allowed. Think of it as a playbook or house rules that prevent people with secret knowledge from getting an unfair advantage; it matters to investors because it helps protect fair markets, preserves trust in management, and reduces the risk of legal penalties that can hurt a company’s value.
broker-dealer financial
"transactions made on the same day at the same price through a trade order executed by a broker-dealer"
A broker-dealer is a licensed firm or individual that both executes trades on behalf of clients (acting as a broker) and buys or sells securities for its own account (acting as a dealer). Investors care because broker-dealers provide the plumbing of markets — they place orders, hold or move cash and securities, offer research or advice, and their stability and fees directly affect trade execution, costs, and the safety of client funds; think of them as a combined travel agent and taxi for your investments.

FAQ

What insider purchases did PLSE report for COO Liane Rae Teplitsky?
COO Liane Rae Teplitsky purchased 1,036 PLSE shares at $48.235 on August 26, 2026 and 1,034 shares at $48.35 on August 28, 2026 in open-market transactions during an open trading window under the company’s Insider Trading Policy.

How many PLSE shares did the COO buy in total in this Form 4?
Across the reported transactions, COO Liane Rae Teplitsky bought a total of 2,070 shares of Pulse Biosciences, Inc. common stock, combining 1,036 shares on August 26, 2026 and 1,034 shares on August 28, 2026.

What prices did the PLSE shares trade at in the COO’s reported purchases?
The reported purchases were made at $48.235 per share for 1,036 shares on August 26, 2026 and $48.35 per share for 1,034 shares on August 28, 2026. Each line aggregates same-day trades executed at the same price through a broker-dealer.

Were the PLSE insider purchases made under a 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not checked. A footnote states the COOs purchases occurred during an open trading window under the company’s Insider Trading Policy and in accordance with applicable securities laws.

How were fractional PLSE shares handled in the COO’s transactions?
A footnote explains that fractional share purchases were rounded down to the nearest whole number in the reported amounts. Thus, the Form 4 shows only whole-share quantities for the 1,036-share and 1,034-share purchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Teplitsky Liane Rae
(Last)(First)(Middle)
C/O PULSE BIOSCIENCES, INC.
3957 POINT EDEN WAY
(Street)
HAYWARD CALIFORNIA 94545
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/26/2026P(1)1,036(2)A$48.235(3)1,036(2)D
Common Stock08/28/2026P(1)1,034(2)A$48.35(3)2,070(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.
2. The purchase of fractional shares has been rounded down to the nearest whole number.
3. Open market purchase transactions made on the same day at the same price through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred at the reported price.
/s/ Kenneth B. Stratton08/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR